Drug intelligence / Profile preview

RM191A

Development stage: Unknown
Lead developer: RR MedSciences
Modality: Small Molecules
Administration: Topical

Overview

RM191A is a patented small molecule copper-amino acid chelate complex developed by RR MedSciences. It functions as a superoxide dismutase (SOD) mimetic, designed to neutralize reactive oxygen and nitrogen species (free radicals) that contribute to inflammatory and immune activation. By mimicking the activity of the innate SOD enzyme, RM191A aims to quench free radicals that activate pain signaling pathways. The drug is primarily being developed as a non-opioid, non-addictive topical treatment (gel or spray) for chronic, severe, and refractory neuropathic pain. It has completed a Phase 2a clinical trial (RRM-CIP-01) at the Royal North Shore Hospital in Sydney, Australia.

Other names: copper-amino acid complexcopper-amino acid chelate complex

Targets

Misfolded SOD1

Beyond the preview

Go deeper on RM191A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RM191A.

Explore the full profile